Oncology Precision Therapeutics and Imaging Core

肿瘤学精密治疗和成像核心：项目总结 肿瘤精确治疗和成像核心（OPTIC）是将精确性 治疗能力纳入现有的小动物影像共享资源的目标，充分提供 为赫伯特欧文综合癌症中心提供转化肿瘤学的综合全面服务 中心（CSCCC）成员。这些措施包括提供成像设备/基础设施， 技术程序、监管支持和用户教育。在Kenneth Olive博士的领导下， OPTIC的使命与个性化医疗的校园范围内的倡议，并补充更多 临床重点的努力，如CIMCC的精确肿瘤学倡议。在本项目期间 （2014-2019年），该委员会已作出了许多重大投资光学，包括：安装一个高- 场9.4T小动物MRI，购买全新IVIS Spectrum光学成像仪，并支持推出 精准治疗服务OPTIC服务分为三大类：（1）新一代 来自主要患者材料的个性化癌症模型，（2）在癌症研究中进行转化治疗研究， 代表用户的小鼠癌症模型，以及（3）小动物成像服务，包括 生物发光/荧光、超声、微型CT和高场MR成像。为了支持这些努力， 成立了机构审查委员会（IRB）和机构动物护理和使用委员会（IACUC） 协议，生成了一组IACUC批准的主成像协议，可以很容易地参考 用户实验室，并集成了一个完整的管道协议的产生，表征，利用， 以及各种肿瘤模型的成像。作为表征新型癌症的OPTIC管道的一部分 模型，OPTIC密切合作，与其他共享资源，包括：基因组学和高 蛋白质组学和大分子晶体学，分子病理学，数据库，和 癌症生物统计学SR。除了提供基本和先进的成像和实验疗法外， 服务，光学经验丰富的成像和翻译科学家也提供咨询和 对实验设计、仪器操作和数据分析方面的培训， 将先进的实验性疗法纳入研究项目组合中。超过 在本项目期间，39个国家协调委员会成员利用了光学技术信息中心的能力，提供了关键数据， 对42项同行评审研究赠款和16项CPCC成员同行评审出版物的见解，包括11项 影响因子>10的期刊中有8篇论文的影响因子>20（Nature，Cell，Nature 医学，癌细胞）。目前，OPTIC支持28项NIH资助的赠款，其中17项来自NCI。

ONCOLOGY PRECISION THERAPEUTICS AND IMAGING CORE: PROJECT SUMMARY The Oncology Precision Therapeutics and Imaging Core (OPTIC) is the result of incorporation of precision therapeutic capabilities into the existing Small Animal Imaging Shared Resource the goal of providing fully integrated and comprehensive services in translational oncology for the Herbert Irving Comprehensive Cancer Center (HICCC) members. These include providing access to imaging equipment/infrastructure, assistance in technical procedures, regulatory support, and user education. Under the leadership of Kenneth Olive, PhD the mission of OPTIC dovetails with a campus-wide initiative in personalized medicine, and complements more clinically focused efforts such as the HICCC’s Precision Oncology Initiative. During the current project period (2014-2019), the HICCC has made numerous major investments in OPTIC, including: the installation of a high- field 9.4T small animal MRI, the purchase of a new IVIS Spectrum optical imager, and support for the launch of precision therapeutic services. OPTIC services fall into three broad categories: (1) the generation of new personalized cancer models from primary patient materials, (2) execution of translational therapeutic studies in mouse models of cancer on behalf of users, and (3) small animal imaging services, including bioluminescent/fluorescent, ultrasound, micro CT, and high-field MR imaging. In support of these efforts, OPTIC has established Institutional Review Board (IRB) and Institutional Animal Care and Use Committee (IACUC) protocols, generated a set of IACUC-approved master protocols for imaging that may be easily referenced by user laboratories, and integrated a complete pipeline of protocols for the generation, characterization, utilization, and imaging of a broad variety of tumor models. As part of the OPTIC pipeline for characterizing novel cancer models, OPTIC collaborates closely with other Shared Resources at the HICCC including: Genomics and High Throughput Screening, Proteomics and Macromolecular Crystallography, Molecular Pathology, DataBase, and Cancer Biostatistics SRs. In addition to providing basic and advanced imaging and experimental therapeutics services, the highly experienced imaging and translational scientists of OPTIC also provide consultation and training to HICCC members in experimental design, instrument operation, and data analysis, which facilitates the incorporation of advanced experimental therapeutics into the research portfolio of HICCC members. Over the current project period, the capabilities of OPTIC were utilized by 39 HICCC members, provided key data and insights for 42 peer-reviewed research grants and 16 HICCC member peer-reviewed publications including 11 papers in journals with impact factor >10 of which 8 were in journals with impact factor >20 (Nature, Cell, Nature Medicine, Cancer Cell). Currently, OPTIC supports research for 28 NIH-funded grants, 17 from NCI.